HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Christian Dior J'Adore Women's Scent To Debut In February

This article was originally published in The Rose Sheet

Executive Summary

J'Adore, the latest addition to Christian Dior's fragrance stable, captures the "essence of the 21st century woman," according to the LVMH subsidiary. J'Adore will bow in February exclusively at Saks Fifth Avenue doors nationwide and Christian Dior boutiques.

You may also be interested in...



Christian Dior CEO Martinez Tasked With Maintaining Double-Digit Growth

Sustaining sales growth of at least 10% is a top priority for newly appointed Christian Dior Parfums President and CEO Claude Martinez, LVMH Perfumes & Cosmetics Group President Patrick Choel said after announcing the appointment May 22.

Christian Dior CEO Martinez Tasked With Maintaining Double-Digit Growth

Sustaining sales growth of at least 10% is a top priority for newly appointed Christian Dior Parfums President and CEO Claude Martinez, LVMH Perfumes & Cosmetics Group President Patrick Choel said after announcing the appointment May 22.

Dior's Three-Year Beauty Plan Expected To Double U.S. Business - CEO Brady

As part of an aggressive plan to more than double Christian Dior's U.S. beauty business by 2003, President and CEO Robert Brady is ramping up its national advertising support and in-store sampling efforts and lighting a fire under its product introduction schedule. Christian Dior is awaiting final approval of the plan from parent company LVMH.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel